TriNetX's Real-World Data and Analytics Platform Used to Compare Antihypertensive Treatments and Cardiovascular Events; Findings Published in the Journal of Clinical Hypertension
CAMBRIDGE, Mass.- TriNetX, the global health research network that optimizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced that the Journal of Clinical Hypertension has published its article on an analysis of first line treatment of essential hypertension using real-world data (RWD). The article, titled First-line treatment of essential hypertension: A real-world analysis across four antihypertensive treatment classes, was written by Manfred Stapff, MD, PhD, Chief Medical Officer at TriNetX, and Sarah Hilderbrand, MSc, and describes how electronic medical records (EMR) can be used to analyze and compare actual treatment practices.
"To my knowledge, this is the first real-world analysis comparing the four antihypertensive classes used as first-line treatment of hypertension with an observation period of three years," said Dr. Stapff. "Not only was real-world data used, but the methodology employed involved a real-world setting rather than an artificial treatment protocol as used in randomized clinical trials (RCT)."
The analysis used EMR data from the TriNetX network to compare patients starting and adhering to antihypertensive treatment on diuretics, beta blockers, RAS blockers (angiotensin II or ACE inhibitors), or calcium channel blockers for at least 36 months. The analysis evaluated cardiovascular events and assessed outcomes with and without propensity score matching for confounding factors.
Dr. Stapff concluded that RWD represents the actual medical practice and allows long-term follow-up periods in a more efficient way than RCTs. The article is currently available for download at the Journal of Clinical Hypertension website at: https://onlinelibrary.wiley.com/doi/full/10.1111/jch.13531
"An advantage of the TriNetX data repository is that it represents a wide range of geographies, ages, and income levels as well as a mix of hospital, primary care, and specialty treatment providers," noted Elizabeth Edwards, MD, MBA and Donald J. DiPette, MD, FAHA, FACP, in an editorial commenting on the TriNetX article. The commentary concludes that "it is time to consider using large repositories of data to a greater extent in the future to determine adherence to current guidelines as well as to guide clinical interventions and decisions," and that "using real-world data…could ultimately save money and increase efficiency." The editorial titled, "Real-world data analysis" in disease management such as hypertension: Has the time come? is also available on the Journal of Clinical Hypertension website at: https://onlinelibrary.wiley.com/doi/full/10.1111/jch.13533
TriNetX has partnered with healthcare organizations spanning 23 countries and thousands of sites, and with data providers covering 99% of US health plans to deploy a linked and continually updated global health research network representing over 300 million patients. TriNetX has been used to analyze over 13,000 protocols and has presented over 3,400 clinical trial opportunities to its HCO members.
TriNetX is the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX at http://www.trinetx.com or follow @TriNetX on Twitter.